251 related articles for article (PubMed ID: 26937194)
1. New developments in the treatment of acute bacterial skin and skin structure infections: considerations for the effective use of dalbavancin.
Juul JJ; Mullins CF; Peppard WJ; Huang AM
Ther Clin Risk Manag; 2016; 12():225-32. PubMed ID: 26937194
[TBL] [Abstract][Full Text] [Related]
2. Once-weekly dalbavancin versus daily conventional therapy for skin infection.
Boucher HW; Wilcox M; Talbot GH; Puttagunta S; Das AF; Dunne MW
N Engl J Med; 2014 Jun; 370(23):2169-79. PubMed ID: 24897082
[TBL] [Abstract][Full Text] [Related]
3. Dalbavancin for the treatment of acute bacterial skin and skin structure infections.
Ramdeen S; Boucher HW
Expert Opin Pharmacother; 2015; 16(13):2073-81. PubMed ID: 26239321
[TBL] [Abstract][Full Text] [Related]
4. Outcomes in Patients with Staphylococcus aureus Bacteremia Treated with Dalbavancin in Clinical Trials.
Gonzalez PL; Rappo U; Akinapelli K; McGregor JS; Puttagunta S; Dunne MW
Infect Dis Ther; 2022 Feb; 11(1):423-434. PubMed ID: 34905144
[TBL] [Abstract][Full Text] [Related]
5. Dalbavancin: A Review in Acute Bacterial Skin and Skin Structure Infections.
Scott LJ
Drugs; 2015 Jul; 75(11):1281-91. PubMed ID: 26105117
[TBL] [Abstract][Full Text] [Related]
6. Dalbavancin for the treatment of acute bacterial skin and skin structure infections.
Esposito S; Noviello S; Leone S
Infez Med; 2015 Dec; 23(4):313-7. PubMed ID: 26700080
[TBL] [Abstract][Full Text] [Related]
7. Dalbavancin: a new lipoglycopeptide antibiotic.
Bailey J; Summers KM
Am J Health Syst Pharm; 2008 Apr; 65(7):599-610. PubMed ID: 18359966
[TBL] [Abstract][Full Text] [Related]
8. Dalbavancin: a review.
Scheinfeld N
Drugs Today (Barc); 2007 May; 43(5):305-16. PubMed ID: 17724497
[TBL] [Abstract][Full Text] [Related]
9. Safety of Dalbavancin in the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI): Nephrotoxicity Rates Compared with Vancomycin: A Post Hoc Analysis of Three Clinical Trials.
Gonzalez PL; Rappo U; Mas Casullo V; Akinapelli K; McGregor JS; Nelson J; Nowak M; Puttagunta S; Dunne MW
Infect Dis Ther; 2021 Mar; 10(1):471-481. PubMed ID: 33515414
[TBL] [Abstract][Full Text] [Related]
10. Dalbavancin: a review for dermatologists.
Scheinfeld N
Dermatol Online J; 2006 May; 12(4):6. PubMed ID: 17083861
[TBL] [Abstract][Full Text] [Related]
11. Dalbavancin: A Novel Lipoglycopeptide Antibiotic with Extended Activity Against Gram-Positive Infections.
Smith JR; Roberts KD; Rybak MJ
Infect Dis Ther; 2015 Sep; 4(3):245-58. PubMed ID: 26341488
[TBL] [Abstract][Full Text] [Related]
12. Activity of dalbavancin tested against Gram-positive clinical isolates causing skin and skin-structure infections in paediatric patients from US hospitals (2014-2015).
Pfaller MA; Mendes RE; Sader HS; Castanheira M; Flamm RK
J Glob Antimicrob Resist; 2017 Dec; 11():4-7. PubMed ID: 28735053
[TBL] [Abstract][Full Text] [Related]
13. Dalbavancin: a new option for the treatment of gram-positive infections.
Lin SW; Carver PL; DePestel DD
Ann Pharmacother; 2006 Mar; 40(3):449-60. PubMed ID: 16507624
[TBL] [Abstract][Full Text] [Related]
14. A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin.
Guskey MT; Tsuji BT
Pharmacotherapy; 2010 Jan; 30(1):80-94. PubMed ID: 20030476
[TBL] [Abstract][Full Text] [Related]
15. Review: dalbavancin--a novel lipoglycopeptide antimicrobial for gram positive pathogens.
Das B; Sarkar C; Biswas R; Pandey S
Pak J Pharm Sci; 2008 Jan; 21(1):78-87. PubMed ID: 18166524
[TBL] [Abstract][Full Text] [Related]
16. A Randomized Clinical Trial of Single-Dose Versus Weekly Dalbavancin for Treatment of Acute Bacterial Skin and Skin Structure Infection.
Dunne MW; Puttagunta S; Giordano P; Krievins D; Zelasky M; Baldassarre J
Clin Infect Dis; 2016 Mar; 62(5):545-51. PubMed ID: 26611777
[TBL] [Abstract][Full Text] [Related]
17. Dalbavancin in the treatment of different gram-positive infections: a real-life experience.
Bouza E; Valerio M; Soriano A; Morata L; Carus EG; Rodríguez-González C; Hidalgo-Tenorio MC; Plata A; Muñoz P; Vena A;
Int J Antimicrob Agents; 2018 Apr; 51(4):571-577. PubMed ID: 29180276
[TBL] [Abstract][Full Text] [Related]
18. Single-Dose Dalbavancin: A Review in Acute Bacterial Skin and Skin Structure Infections.
Garnock-Jones KP
Drugs; 2017 Jan; 77(1):75-83. PubMed ID: 27988870
[TBL] [Abstract][Full Text] [Related]
19. Clinical efficacy of dalbavancin for the treatment of acute bacterial skin and skin structure infections (ABSSSI).
Leuthner KD; Buechler KA; Kogan D; Saguros A; Lee HS
Ther Clin Risk Manag; 2016; 12():931-40. PubMed ID: 27354809
[TBL] [Abstract][Full Text] [Related]
20. Beyond Vancomycin: The Tail of the Lipoglycopeptides.
Klinker KP; Borgert SJ
Clin Ther; 2015 Dec; 37(12):2619-36. PubMed ID: 26658277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]